GTN
MCID: GST010
MIFTS: 46

Gestational Trophoblastic Neoplasm (GTN)

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Gestational Trophoblastic Neoplasm

MalaCards integrated aliases for Gestational Trophoblastic Neoplasm:

Name: Gestational Trophoblastic Neoplasm 12 52 58 15
Hydatidiform Mole 12 43 15 71
Gestational Trophoblastic Disease 43 71
Gestational Trophoblastic Tumor 52 54
Gtn 52 58
Gestational Trophoblastic Neoplasia 12
Gestational Trophoblastic Neoplasms 71
Hydatidiform Mole, Recurrent, 1 71
Molar Pregnancy 12

Characteristics:

Orphanet epidemiological data:

58
gestational trophoblastic neoplasm
Inheritance: Not applicable; Age of onset: Adult; Age of death: adult;

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:3590
ICD9CM 34 630
SNOMED-CT 67 48430004 609519004
ICD10 32 O01
MESH via Orphanet 44 D031901
UMLS via Orphanet 72 C1135868
Orphanet 58 ORPHA59305
SNOMED-CT via HPO 68 17369002 314631008 351814001
UMLS 71 C0020217 C0278796 C1135868 more

Summaries for Gestational Trophoblastic Neoplasm

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 59305 Definition Gestational trophoblastic tumors (GTT) are malignant forms of gestational trophoblastic disease. The tumor always follows pregnancy, most often molar pregnancy (hydatidiform mole; see this term). Four histological subtypes have been described: invasive mole, gestational choriocarcinoma, placental site trophoblastic tumor and epithelioid trophoblastic tumor (see these terms). Epidemiology Exact annual incidence is not known but it is estimated to be about 1/1,000,000 women. Clinical description GTTs occur following hydatidiform moles (see this term) (15% of complete moles and about 3% of partial moles), following spontaneous miscarriage (1/150) or childbirth (1/40,000). Indicative signs are an absence of normalization or a secondary elevation of total serum chorionic gonadotropin (hCG) levels after evacuation of a hydatidiform mole (more than 60% of cases), persistent unexplained metrorrhagia following spontaneous miscarriage or voluntary termination of pregnancy (VTP) (about 30% of cases) and very occasionally, unexplained metrorrhagia in the weeks or months following normal childbirth or ectopic pregnancy (about 10% of cases). Exceptionally, metastasis may be a sign of the disease in women of childbearing age. Etiology The etiology of gestational trophoblastic tumors is not known. Identification of a GTT is based on a total serum hCG assay, which is recommended following hydatidiform moles in patients with metrorrhagia persisting for more than six weeks after pregnancy, and in any patient of childbearing age who has metastasis (lung, liver, brain, kidney, vagina) with no known primary tumor. Diagnostic methods Diagnosis of a post-molar GTT relies on one of the following four criteria: stable hCG levels (variation of less than 10%) with at least four weekly assays over a period of at least three weeks (days 1, 7, 14, 21), increase of at least 10% in hCG with at least three weekly assays over at least two weeks (days 1, 7, 14), persistence of detectable hCG values for more than six months following mole evacuation or based on histological diagnosis of a choriocarcinoma. Differential diagnosis GTTs must not be confused with hydatidiform moles (see this term) and, for choriocarcinomas, with non-gestational choriocarcinomas, which are most often ovarian. Management and treatment As soon as the diagnosis is made, staging must be performed to identify frequent metastases. Staging involves endovaginal pelvic color doppler ultrasound , pelvic and cerebral MRI , and abdominal/chest CT. A lung X-ray must be performed to calculate the FIGO 2000 score (International Federation of Obstetrics and Gynecology) in case of lung metastasis on CT. This score makes it possible to distinguish between low-risk GTTs (score of 6 or lower) and high-risk GTTs (score of 7 or higher). Management should be multidisciplinary and must be discussed by a panel of physicians in a specialized center. Low-risk tumors are treated by systemic single-agent chemotherapy , e.g. methotrexate (marketing authorization). High-risk tumors are treated first line with systemic multi-agent chemotherapy. Hysterectomy can of course not be considered for first-line treatment in women who wish to become pregnant, unless there is no option. Placental site trophoblastic tumors and epithelioid trophoblastic tumors are special cases: the FIGO score is not appropriate and total hysterectomy is the standard treatment as these tumors are usually chemo-resistant. Prognosis The overall recovery rate is around 99%. The prognosis is very closely related to the rapidity of diagnosis, the risk level of the tumor (low or high) and the suitability of treatment. Visit the Orphanet disease page for more resources.

MalaCards based summary : Gestational Trophoblastic Neoplasm, also known as hydatidiform mole, is related to partial hydatidiform mole and hydatidiform mole, recurrent, 1. An important gene associated with Gestational Trophoblastic Neoplasm is H19 (H19 Imprinted Maternally Expressed Transcript). The drugs Amifostine and Clotrimazole have been mentioned in the context of this disorder. Affiliated tissues include placenta, lung and bone, and related phenotypes are spontaneous abortion and high maternal serum chorionic gonadotropin

Related Diseases for Gestational Trophoblastic Neoplasm

Diseases related to Gestational Trophoblastic Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 284)
# Related Disease Score Top Affiliating Genes
1 partial hydatidiform mole 35.3 NLRP7 KHDC3L
2 hydatidiform mole, recurrent, 1 33.1 NLRP7 KHDC3L H19 CGB5 CDKN1C
3 placental site trophoblastic tumor 32.7 PAM NR0B1 LGALS1 CSH2 CSH1 CGB5
4 triploidy 32.2 NLRP7 KHDC3L
5 pre-eclampsia 31.5 H19 CSH2 CSH1 CGB5
6 choriocarcinoma 31.1 H19 CSH2 CSH1 CGB5 CDKN1C
7 placenta disease 30.9 LGALS1 CSH2 CSH1 CGB5
8 epithelioid trophoblastic tumor 30.7 LGALS1 CSH2 CSH1
9 gestational choriocarcinoma 30.4 NLRP7 H19 CSH2 CSH1 CGB5
10 beckwith-wiedemann syndrome 29.4 ZFP57 PLAGL1 NLRP7 NLRP5 NLRP2 KHDC3L
11 silver-russell syndrome 1 29.1 ZFP57 PLAGL1 NLRP7 NLRP5 NLRP2 KHDC3L
12 trophoblastic neoplasm 28.5 PRB1 PLAGL1 PAM OOEP NR0B1 NLRP7
13 recurrent hydatidiform mole 13.1
14 hydatidiform mole, recurrent, 2 13.1
15 hydatidiform mole, recurrent, 3 13.0
16 hydatidiform mole, recurrent, 4 13.0
17 pulmonary arteriovenous fistulas 11.7
18 hyperthyroidism, familial gestational 11.2
19 eclampsia 10.9
20 hyperthyroidism 10.9
21 ectopic pregnancy 10.8
22 severe pre-eclampsia 10.7
23 chromosomal triplication 10.7
24 graves disease 1 10.7
25 placenta praevia 10.7
26 ovarian cyst 10.6
27 tetraploidy 10.6
28 infertility 10.6
29 pemphigoid gestationis 10.5
30 testicular trophoblastic tumor 10.5 CSH2 CSH1
31 ovarian hyperstimulation syndrome 10.5
32 rete ovarii adenoma 10.5 CSH2 CSH1
33 rete ovarii benign neoplasm 10.5 CSH2 CSH1
34 gestational ovarian choriocarcinoma 10.5 CSH2 CSH1
35 choriocarcinoma of ovary 10.5 CSH2 CSH1
36 choriocarcinoma of the testis 10.4 CSH2 CSH1
37 47,xyy 10.4
38 migraine with or without aura 1 10.4
39 non-gestational ovarian choriocarcinoma 10.4 CSH2 CSH1
40 hemihyperplasia, isolated 10.4 H19 CDKN1C
41 paternal uniparental disomy of chromosome 6 10.4 PLAGL1 HYMAI
42 rh isoimmunization 10.4 CSH2 CSH1
43 non-gestational choriocarcinoma 10.4 CSH2 CSH1
44 headache 10.4
45 anencephaly 10.4
46 nephrotic syndrome 10.4
47 overgrowth syndrome 10.4
48 wilms tumor predisposition 10.4 H19 CDKN1C
49 invasive mole 10.4
50 neutropenia 10.4

Graphical network of the top 20 diseases related to Gestational Trophoblastic Neoplasm:



Diseases related to Gestational Trophoblastic Neoplasm

Symptoms & Phenotypes for Gestational Trophoblastic Neoplasm

Human phenotypes related to Gestational Trophoblastic Neoplasm:

58 31
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 spontaneous abortion 58 31 hallmark (90%) Very frequent (99-80%) HP:0005268
2 high maternal serum chorionic gonadotropin 58 31 hallmark (90%) Very frequent (99-80%) HP:0011433
3 menometrorrhagia 58 31 hallmark (90%) Very frequent (99-80%) HP:0400008

Drugs & Therapeutics for Gestational Trophoblastic Neoplasm

Drugs for Gestational Trophoblastic Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 170)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amifostine Approved, Investigational Phase 3 20537-88-6 2141
2
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
3
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
4
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
5
Captopril Approved Phase 3 62571-86-2 44093
6
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
7
Ribavirin Approved Phase 3 36791-04-5 37542
8
Palivizumab Approved, Investigational Phase 3 188039-54-5
9
Acyclovir Approved Phase 3 59277-89-3 2022
10
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
11
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
12
Sodium citrate Approved, Investigational Phase 3 68-04-2
13
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
14
leucovorin Approved Phase 3 58-05-9 6006 143
15
Nitroglycerin Approved, Investigational Phase 2, Phase 3 55-63-0 4510
16
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
17
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
18
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
19
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
20
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
21
Etoposide Approved Phase 3 33419-42-0 36462
22
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
23
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
24
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
25
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
26
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
27
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
28
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
29
Polyestradiol phosphate Approved Phase 3 28014-46-2
30
Mycophenolic acid Approved Phase 3 24280-93-1 446541
31
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
32
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
33
Enclomiphene Investigational Phase 3 15690-57-0
34 Anti-Infective Agents Phase 3
35 Anti-Bacterial Agents Phase 3
36 Liver Extracts Phase 3
37 Radiation-Protective Agents Phase 3
38 Immunoglobulins Phase 3
39 Antibodies Phase 3
40 Hormone Antagonists Phase 3
41 Antiviral Agents Phase 3
42 HIV Protease Inhibitors Phase 3
43
protease inhibitors Phase 3
44 Antibodies, Monoclonal Phase 3
45 Cytochrome P-450 Enzyme Inhibitors Phase 3
46
Hydroxyitraconazole Phase 3
47 Antifungal Agents Phase 3
48 Cytochrome P-450 CYP3A Inhibitors Phase 3
49 Antihypertensive Agents Phase 3
50 Angiotensin-Converting Enzyme Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 86)
# Name Status NCT ID Phase Drugs
1 A Comparison of Single Versus Double Evacuation for Treatment of Hydatidiform Unknown status NCT01630954 Phase 4
2 Primary Surgery Plus Single Course Methotrexate Versus Primary Methotrexate for Treatment of Gestational Trophoblastic Neoplasms in Low Risk Cases Above 40y: a Randomized Controled Trial Unknown status NCT02606539 Phase 2, Phase 3 Methotrexate plus folinic acid alone
3 Comparison Between Rescue Regimen and High Dose Methotrexate in the Managment of Presistent Gestational Trophoplastic Neoplasia :( A Randomized Controlled Trial ) Unknown status NCT03280979 Phase 2, Phase 3 rescue regimen;high dose methotrxate
4 A Randomized Phase III Trial of Weekly Parenteral Methotrexate Versus "Pulsed" Dactinomycin as Primary Management for Low Risk Gestational Trophoblastic Neoplasia Completed NCT00003702 Phase 3 Methotrexate
5 The Efficacy of Methotrexate for the Prevention of Postmolar Gestational Trophoblastic Disease Among Patients With High-Risk Hydatidiform Mole Completed NCT01984099 Phase 3 Methotrexate;Vitamin B Complex
6 A Randomized Phase III Trial of Amifostine vs. No Treatment for Platinum Induced Peripheral Neuropathy Completed NCT00058071 Phase 3 amifostine trihydrate
7 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
8 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
9 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
10 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
11 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
12 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
13 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
14 Study On The Effects of Letrozole And Clomiphene Citrate For Induction of Ovulation In Polycystic Ovarian Syndrome(PCOS) Completed NCT01577017 Phase 3 Letrozole
15 A Prospective Randomized Multicenter Clinical Control Study of Hysteroscopic Repeat Curettage as the Primal Management of Low-risk Postmolar Gestational Trophoblastic Neoplasia Recruiting NCT03703271 Phase 3 Methotrexate
16 A Prospective Randomized Multicenter Clinical Control Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor Recruiting NCT02639650 Phase 3 Etoposide;actinomycin D;methotrexate;vincristine;cyclophosphamide;Paclitaxel;Cisplatin;Carboplatin
17 Women's Hospital, Zhejiang University School of Medicine Recruiting NCT03885388 Phase 2, Phase 3 MTX;MTX+ACTD
18 A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia Active, not recruiting NCT01535053 Phase 3 Leucovorin Calcium;Methotrexate
19 A Multicenter, Prospective, Randomized Trial of Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia Active, not recruiting NCT01823315 Phase 3 MTX 1;MTX 2
20 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
21 A Randomized Study to Evaluate The Efficacy of Mycophenolate Mofetil Added to The Systemic Immunosuppressive Regimen First Used For Treatment of Chronic Graft-Versus-Host Disease Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
22 Pulse Actinomycin-D as Salvage Therapy for Failed Low Risk Gestational Trophoblastic Neoplasia Completed NCT00003688 Phase 2
23 A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia Completed NCT00521118 Phase 2
24 A Phase II Trial of Pemetrexed (Alimta) in the Treatment of Recurrent or Persistent Low Risk Gestational Trophoblastic Tumor Completed NCT00190918 Phase 2 Pemetrexed
25 A Phase II Study to Evaluate Low-Dose Alemtuzumab as a Glucocorticoid-Sparing Agent for Initial Systemic Treatment of Acute Graft-Versus-Host Disease Completed NCT00410657 Phase 2 methylprednisolone;prednisone
26 Phase II Clinical Trial Incorporating Alemtuzumab (Campath-1H) in Combination With FK506 and Methylprednisolone for Treatment of Severe Acute Graft vs Host Disease Completed NCT00109993 Phase 2 methylprednisolone;tacrolimus
27 Combination of Interleukin 11 (Neumega) With G-CSF to Mobilize Autologous Peripheral Blood Stem Cells (PBSC) Completed NCT00004157 Phase 2
28 Donor Lymphocyte Infusion (DLI) as Adoptive Immunotherapy for Relapse Malignancies After Allogeneic Hematopoietic Transplantation Completed NCT00003887 Phase 2
29 Oral Beclomethasone Dipropionate Capsules for Treatment of Intestinal Graft-Versus-Host Disease: Compassionate Use in Patients With Contraindictions to High-Dose Immunosuppressive Therapy Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate
30 Cytokine-Based Immunotherapy Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation Completed NCT00003408 Phase 2
31 A Phase I-II Safety, Tolerability And Pharmacokinetic Study Of Ravuconazole For Prophylaxis Of Invasive Fungal Infections In Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT00064311 Phase 1, Phase 2 ravuconazole
32 Psychosexual Intervention for Gynecologic and Breast Cancer Patients Completed NCT01764802 Phase 2
33 Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells Completed NCT00795769 Phase 2 ondansetron
34 A Phase II Study to Evaluate Efficacy and Tolerability of Methotrexate in Combination With Glucocorticoids for the Treatment of Newly Diagnosed Acute Graft-Versus-Host Disease After Nonmyeloablative Hematopoietic Cell Transplantation Completed NCT00357084 Phase 2 methotrexate;methylprednisolone;prednisone
35 A PHASE II STUDY OF CELLULAR ADOPTIVE IMMUNOTHERAPY AS PROPHYLAXIS FOR CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION Completed NCT00002673 Phase 2
36 A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Completed NCT00110045 Phase 2 caspofungin acetate
37 A Phase II Trial of Avelumab in Chemo-resistant Gestational Trophoblastic Neoplasias (GTN) Recruiting NCT03135769 Phase 2 Avelumab administration at 10mg/kg
38 TROPHAMET, a Phase I/II Trial of Avelumab and METhotrexate in Low-risk Gestational TROPHoblastic Neoplasias as First Line Treatment Recruiting NCT04396223 Phase 1, Phase 2 Avelumab Injection;Methotrexate 1 GM Injection
39 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
40 Camrelizumab Combined With Apatinib for Recurrent Resistant Gestational Trophoblastic Neoplasia: a Phase 2, Single-arm, Prospective Study Active, not recruiting NCT04047017 Phase 2 Apatinib;Camrelizumab
41 Phase 2 Trial for Chemo-Resistant Gestational Trophoblastic Neoplasias With Pembrolizumab Not yet recruiting NCT04303884 Phase 2 Pembrolizumab Injection [Keytruda]
42 A Phase II Trial of Pemetrexed (ALIMTA®, LY231514, IND #40061) as Salvage Therapy for Failed Low Risk Gestational Trophoblastic Tumor Terminated NCT00096187 Phase 2 pemetrexed disodium
43 A Phase 2A Study of TRC105 (With Option to Add Bevacizumab) in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN) Terminated NCT02664961 Phase 2 TRC105;Bevacizumab
44 Deferasirox Treatment and Labile Plasma Iron in Iron Overloaded Patients Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT01159067 Phase 2 deferasirox
45 Emergency Access to C.V. pp65 / IE-1 Specific Cytotoxic T Lymphocytes for Recipients of Allogeneic Stem Cell Transplants With Persistant or Therapy Refractory Infections Unknown status NCT00769613 Phase 1
46 A Phase I Trial of Recombinant Human Interleukin-12 After High-Dose Therapy and Autologous Hematopoietic Stem Cell Support Completed NCT00003107 Phase 1
47 Prolonged Infusion Compared to Standard Infusion Cefepime as Empiric Treatment of Febrile Neutropenia: A Pilot Study Completed NCT01484015 Phase 1 cefepime hydrochloride
48 Phase I Study of Intraperitoneal Administration of 9-Amino-20(S)-Camptothecin to Patients With Cancer Predominantly Confined to the Peritoneal Cavity Completed NCT00003548 Phase 1 aminocamptothecin colloidal dispersion
49 A Phase I Clinical Trial of Intrapleural Adenoviral-Mediated Interferon-beta (IFN-ß) Gene Transfer for Pleural Malignancies Completed NCT00066404 Phase 1
50 A Phase I Study of Thrombopoietin (rhTPO) Plus G-CSF in Children Receiving Ifosfamide, Carboplatin, and Etoposide (I.C.E.) Chemotherapy for Recurrent or Refractory Solid Tumors Completed NCT00003597 Phase 1 carboplatin;etoposide;ifosfamide

Search NIH Clinical Center for Gestational Trophoblastic Neoplasm

Cochrane evidence based reviews: hydatidiform mole

Genetic Tests for Gestational Trophoblastic Neoplasm

Anatomical Context for Gestational Trophoblastic Neoplasm

MalaCards organs/tissues related to Gestational Trophoblastic Neoplasm:

40
Placenta, Lung, Bone, Testes, Liver, Bone Marrow, Kidney

Publications for Gestational Trophoblastic Neoplasm

Articles related to Gestational Trophoblastic Neoplasm:

(show top 50) (show all 2798)
# Title Authors PMID Year
1
Criteria for initiating chemotherapy in patients after evacuation of hydatidiform mole. 61 54
14610317 2003
2
Spliceosome protein EFTUD2 is upregulated in the trophoblast of spontaneous miscarriage and hydatidiform mole. 61
32447180 2020
3
Hydatidiform mole in the era of COVID-19 pandemic. Is there an association? 61
32320102 2020
4
Hemoptysis as the first symptom in the diagnosis of metastatic choriocarcinoma in the third trimester of pregnancy: A case report. 61
32426244 2020
5
Genetically Related Choriocarcinoma Developing 5 Yr After a Complete Hydatidiform Mole and Simulating a Cornual Ectopic Pregnancy. 61
31033803 2020
6
Evaluation of a routine second curettage for hydatidiform mole: a cohort study. 61
32144509 2020
7
Abnormal processing of IL-1β in NLRP7-mutated monocytes in hydatidiform mole patients. 61
32484253 2020
8
Germline NLRP7 mutations: genomic imprinting and hydatidiform mole. 61
32577811 2020
9
Gynecologic cancer in pregnancy. 61
32268951 2020
10
MiR-30a-5p inhibits proliferation and metastasis of hydatidiform mole by regulating B3GNT5 through ERK/AKT pathways. 61
32575164 2020
11
A case of unplanned pregnancy at 2 months after uterine curettage in a patient with a hydatidiform mole. 61
32495669 2020
12
Prevalence of Partial Hydatidiform Mole in Products of Conception From Gestations With Fetal Triploidy Merits Reflex Genotype Testing Independent of the Morphologic Appearance of the Chorionic Villi. 61
32205485 2020
13
Comprehensive analysis of 204 sporadic hydatidiform moles: revisiting risk factors and their correlations with the molar genotypes. 61
31857680 2020
14
Differential expression of SALL4 in CTCs derived from hydatidiform moles and gestational trophoblastic neoplasms. 61
32187420 2020
15
p57-discordant villi in hydropic products of conception: a clinicopathological study of 70 cases. 61
32387104 2020
16
Hydatidiform mole in a scar on the uterus: A case report. 61
32368549 2020
17
Whole transcriptome analysis of gestational trophoblastic neoplasms reveals altered PI3K signaling pathway in epithelioid trophoblastic tumor. 61
31954539 2020
18
Obstetric outcomes of twin pregnancies presenting with a complete hydatidiform mole and coexistent normal fetus: a systematic review and meta-analysis. 61
32339446 2020
19
Cell-Free DNA as an Addition to Ultrasound for Screening of a Complete Hydatidiform Mole and Coexisting Normal Fetus Pregnancy: A Case Report. 61
32566367 2020
20
Thiol/Disulfide Homeostasis in Patients with Molar Pregnancies. 61
31304870 2020
21
Identification of a hydatidiform mole in twin pregnancy following assisted reproduction. 61
31833013 2020
22
A review on management of gestational trophoblastic neoplasia. 61
32509606 2020
23
[Clinicopathological features of myeloid sarcoma and DLBCL in the breast: a comparative study]. 61
32187897 2020
24
Improved assembly and variant detection of a haploid human genome using single-molecule, high-fidelity long reads. 61
31711268 2020
25
An Incidental Ultrasonographic Diagnosis of Partial Hydatidiform Mole in a Old Primigravida: A Case Report. 61
32335624 2020
26
Epithelioid trophoblastic tumor in a postmenopausal woman: A case report and review of the literature in the postmenopausal group. 61
32108639 2020
27
A challenging case of twin pregnancy with complete hydatidiform mole and co-existing normal live fetus - A case report and review of the literature. 61
31890831 2020
28
Placental mesenchymal dysplasia in a normal female infant: a rare case report with follow-up. 61
32509060 2020
29
Complete Hydatidiform Mole Mimicking Sacroiliitis. 61
32000225 2020
30
Coexisting complete hydatidiform mole & live pregnancy. 61
32134022 2020
31
Parentage of Hydatidiform Moles. 61
31999355 2020
32
Complete Hydatidiform Mole and Co-Existing Live Fetus after Intracytoplasmic Sperm Injection: A Case Report and Literature Review. 61
31997691 2020
33
Loss of p57KIP2 expression confers resistance to contact inhibition in human androgenetic trophoblast stem cells. 61
31792181 2019
34
A KHDC3L mutation resulting in recurrent hydatidiform mole causes genome-wide DNA methylation loss in oocytes and persistent imprinting defects post-fertilisation. 61
31847873 2019
35
[Clinical characteristics and diagnosis of early hydatidiform mole]. 61
31752459 2019
36
Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. 61
31693991 2019
37
A case report of pelviscopic resection of invasive hydatidiform mole. 61
31593140 2019
38
Heuristic neural network approach in histological sections detection of hydatidiform mole. 61
31720313 2019
39
Complete hydatidiform mole with a twin pregnancy at 26 weeks: a rare obstetric complication. 61
31641655 2019
40
Is a Complete Hydatidiform Mole and a Co-existing Normal Fetus an Iatrogenic Effect? 61
31599505 2019
41
Termination of a partial hydatidiform mole and coexisting fetus: A case report. 61
31667181 2019
42
Overexpression of iASPP is required for autophagy in response to oxidative stress in choriocarcinoma. 61
31615473 2019
43
Microsatellite DNA Genotyping and Flow Cytometry Ploidy Analyses of Formalin-fixed Paraffin-embedded Hydatidiform Molar Tissues. 61
31680667 2019
44
Choriocarcinoma After Normal Vaginal Delivery; A Rare Entity. 61
31933325 2019
45
Ovarian hyperstimulation syndrome following surgical removal of a complete hydatidiform mole: a case report. 61
31506106 2019
46
Clinical characteristics and outcomes of extrauterine epithelioid trophoblastic tumors. 61
31312959 2019
47
p57 in Hydatidiform Moles: Evaluation of Antibodies and Expression in Various Cell Types. 61
31567274 2019
48
Molecular cytogenetic analysis of a hydatidiform mole with coexistent fetus: a case report. 61
31421684 2019
49
Persistent free-floating pelvic trophoblastic cysts following an interstitial ectopic pregnancy. 61
31439571 2019
50
Imaging in Gestational Trophoblastic Disease. 61
31375173 2019

Variations for Gestational Trophoblastic Neoplasm

Expression for Gestational Trophoblastic Neoplasm

Search GEO for disease gene expression data for Gestational Trophoblastic Neoplasm.

Pathways for Gestational Trophoblastic Neoplasm

GO Terms for Gestational Trophoblastic Neoplasm

Cellular components related to Gestational Trophoblastic Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 PRB1 PAM LGALS1 CTSC CSH2 CSH1
2 apical cortex GO:0045179 8.62 OOEP KHDC3L

Biological processes related to Gestational Trophoblastic Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.55 PLAGL1 NLRP2 LGALS1 CTSC CGB5
2 positive regulation of JAK-STAT cascade GO:0046427 9.32 CSH2 CSH1
3 animal organ development GO:0048513 9.26 CSH2 CSH1
4 growth hormone receptor signaling pathway GO:0060396 8.96 CSH2 CSH1
5 positive regulation of growth GO:0045927 8.62 CSH2 CSH1

Molecular functions related to Gestational Trophoblastic Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.13 CSH2 CSH1 CGB5
2 growth hormone receptor binding GO:0005131 8.62 CSH2 CSH1

Sources for Gestational Trophoblastic Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....